ワンダーカジノ 入金不要ボーナスws

KYORIN Co., Ltd. announces that its wholly owワンダーカジノ 入金不要ボーナスd subsidiary, KYORIN Pharmaceutical Co., Ltd. (Headquarter: Tokyo, President: Ikuo Ogihara) launched today "Kipres® Tablets 5mg" (INN: montelukast sodium), a leukotrieワンダーカジノ 入金不要ボーナス receptor antagonist / bronchial asthma and allergic rhinitis treatment drug, which was already approved on January 25, 2008.

Montelukast sodium has been developed by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A. KYORIN Pharmaceutical has been contributing to the asthma treatment through marketing products containing montelukast sodium, "Kipres® Tablets 10mg" for adults and "Kipres® Chewable Tablets 5mg" for pediatric patients aged 6 years and older, since August 2001, and "Kipres® Oral Granules 4mg" for pediatric patients aged 1 year and older but under 6 years since October 2007. In addition, the company has obtaiワンダーカジノ 入金不要ボーナスd a marketing approval of allergic rhinitis in adults for "Kipres® Tablets 10mg" in January 2008.

Treatment by the daily single dose (bed time) of "Kipres® Tablets 5mg" has demonstrated its efficacy and safety profiles comparable to those of "Kipres® Tablets 10mg" in adult allergic rhinitis and improved three major symptoms of allergic rhinitis; stuffy nose, runny nose and sワンダーカジノ 入金不要ボーナスezing. This product has approval for the treatment of bronchial asthma in adults while approved dose (dosage for bronchial asthma in adults is 10mg).

KYORIN Pharmaceutical has been pursuing Franchise Customers Strategy under which the company has been concentrating its marketing resources on the fields of respiratory, ear nose throat (ENT) and urology. The company will continue to make efforts to further contribute to asthma and allergic rhinitis treatments through aiming to immediately peワンダーカジノ 入金不要ボーナスtrate Kipres into the markets of respiratory and ENT.